Gilead Sciences (GILD) Estimates, PT Lowered at Baird

October 18, 2016 6:58 AM EDT Send to a Friend
Baird analyst Brian Skorney lowered 3Q16 Hep C estimates and his price target on Outperform-rated Gilead Sciences (NASDAQ: GILD) to ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login